Bioinformatic Solutions LLC

Bioinformatic Solutions LLC, a small disadvantaged business based in Sheridan, Wyoming, operates exclusively as a sub-recipient on federal research grants in the life sciences and neurobiology space, with no prime contract or grant awardee history in the source data. The company is structured as a limited liability partnership and self-certifies as a small disadvantaged business.

Across three sub-awards obligated at $213 thousand combined, Bioinformatic Solutions LLC has partnered with The Regents of the University of Colorado as the prime grant recipient on three National Institutes of Health projects spanning three distinct NIH institutes. The work includes a January 2026 sub-award on insulin and nutrient actions in the fetal liver (National Institute of Diabetes and Digestive and Kidney Diseases), an October 2025 sub-award on retinal development competence and fate choice dynamics (National Eye Institute), and a July 2024 sub-award on axonal signaling and oligodendrocyte differentiation (National Institute of Neurological Disorders and Stroke). All three sub-awards flow through University of Colorado as the administrative prime and reflect bioinformatics research support rather than contract services.

Customer concentration is distributed across three separate NIH institutes rather than concentrated — each institute accounts for one award. Award activity has remained flat at one sub-award per year since mid-2024, with no visible growth trajectory. The company operates entirely in the life sciences research sub-award space with no visible prime contracting capability or independent federal vehicle participation; competitive overlap would be limited to other bioinformatics research support vendors competing for similar university-embedded research sub-awards rather than prime federal contractors.